September 14, 2023
- August 14, 2023 - Understanding and Mitigating Health Disparities experienced by People with Disabilities caused by Ableism (R01 Clinical Trial Optional). See NOFO RFA-HD-24-007.
- November 6, 2023 - Notice of Technical Assistance Webinar and FAQs for RFA-HD-24-007. See NOFO NOT-HD-23-034.
National Cancer Institute (NCI)
The purpose of this Notice is to add National Cancer Institute's (NCI) research interests in RFA-HD-24-007, Understanding and Mitigating Health Disparities experienced by People with Disabilities caused by Ableism (R01 Clinical Trial Optional).
The following section of RFA-HD-24-007 has been modified to reflect NCI's research interests in bold italics:
Part 2. Full Text of Announcement, Section I. Notice of Funding Opportunity Description
The following paragraph has been inserted (below NIBIB Statement of Interest) to state NCI’s Statement of Interest (in bold italics)
NIBIB Statement of Interest
This mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to transform through engineering the understanding of disease and its prevention, detection, diagnosis, and treatment. Under this NOFO, NIBIB will support applications that propose to develop or redesign medical technologies aimed at mitigating the health impacts of ableism. To specifically meet the needs of populations with disabilities, applications developing novel technologies should incorporate a universal design approach and those building on existing technologies should provide significantly improved accessibility and ease-of-use for all. Projects may span the development in research settings, validation, translation into clinical settings as needed, and incorporation of these solutions as endpoints into research protocols.
Applicants are strongly encouraged to contact the NIBIB Scientific Contact listed below to discuss the relevance of their proposed topic(s) to the research mission of NIBIB.
For applications proposing clinical trials, NIBIB funding of clinical trials will be in accordance with NOT-EB-21-005 NIBIB Guidance for Support of Clinical Trial Applications." Briefly, NIBIB will only support mission-focused early-stage clinical trial applications, i.e., feasibility, Phase I, first-in-human, safety, or other small clinical trials, that inform early-stage technology development. NIBIB will not support applications proposing pivotal, Phase II, III, IV, or trials in which the primary outcome is efficacy, effectiveness, or a post-market concern. Also, mechanistic trials are not supported unless the primary focus of the project is on technology development.
NCI Statement of Interest
The National Cancer Institute (NCI) is interested in supporting research that addresses how ableism presents barriers to timely cancer preventive care, screening, diagnosis, treatment, and follow-up, and impedes access to and delivery of cancer care that contributes to health disparities for persons with physical/mobility and/or sensory (e.g., vision loss, hearing loss) disabilities. NCI seeks to generate new knowledge that will help mitigate ableist attitudes and the stigma of disability so that persons with disabilities (PWD) can receive guideline-concordant cancer care. In addition, NCI is interested in understanding the effects of structural ableism, which includes the physical barriers, policies, laws, and practices that exclude PWD from equal opportunity, and how these affect the quality of cancer care and contribute to health disparities, especially for PWD who are members of medically underserved minority or marginalized groups.
Research areas of interest include, but are not limited to:
- Understanding how the intersection of ableism with other forms of oppression (e.g., racism, homophobia, sexism, income inequality) affects the quality of cancer preventive care, diagnosis, treatment, and follow-up care, and contributes to cancer health disparities for PWD
- Developing strategies to improve participation of PWD in medical research and clinical trials
- Developing models of healthcare delivery that support PWD receiving guideline-concordant cancer care
Applicants are encouraged to contact the NCI Scientific Contact to discuss the relevance of their proposed project to the research mission of NCI.
Section II. Award Information
Funds Available and Anticipated Number of Awards
NICHD intends to commit $1,600,000 total costs in FY 2024 to fund 2-3 awards.
NEI intends to commit $1,500,000 total costs in FY2024 to fund 2-3 awards.
NIBIB intends to commit $800,000 total costs in FY2024 to fund 1 award.
NCI proposes to commit $650,000 total costs in FY2024
All other aspects of RFA-HD-24-007 remain unchanged.
Wendy Nelson, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240.276.6971
Email: [email protected]
and Human Services (HHS)
